NasdaqCM:ZSAN

Stock Analysis Report

Executive Summary

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology.

Snowflake

Fundamentals

Adequate balance sheet and overvalued.


Similar Companies

Share Price & News

How has Zosano Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-5.1%

NasdaqCM:ZSAN

-0.6%

US Medical Equipment

-0.7%

US Market


1 Year Return

-30.2%

NasdaqCM:ZSAN

14.5%

US Medical Equipment

-0.5%

US Market

ZSAN underperformed the Medical Equipment industry which returned 14.5% over the past year.

ZSAN underperformed the Market in United States of America which returned -0.4% over the past year.


Share holder returns

ZSANIndustryMarket
7 Day-5.1%-0.6%-0.7%
30 Day-14.5%-0.07%-3.0%
90 Day3.4%10.5%0.9%
1 Year-30.2%-30.2%15.4%14.5%1.7%-0.5%
3 Year-88.0%-88.0%66.9%61.7%39.5%30.4%
5 Yearn/a131.4%104.8%54.1%37.0%

Price Volatility Vs. Market

How volatile is Zosano Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Zosano Pharma undervalued based on future cash flows and its price relative to the stock market?

2.46x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Zosano Pharma to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Zosano Pharma to establish if it is available at substantial discount.


Price Based on Earnings

Zosano Pharma is loss making, we can't compare its value to the US Medical Equipment industry average.

Zosano Pharma is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Zosano Pharma, we can't assess if its growth is good value.


Price Based on Value of Assets

Zosano Pharma is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Zosano Pharma expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

8.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if Zosano Pharma is high growth as no revenue estimate data is available.

Zosano Pharma is not considered high growth as it is expected to be loss making for the next 1-3 years.

Unable to compare Zosano Pharma's revenue growth to the United States of America market average as no estimate data is available.

Unable to compare Zosano Pharma's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Zosano Pharma's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Zosano Pharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Zosano Pharma performed over the past 5 years?

-14.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Zosano Pharma does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Zosano Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Zosano Pharma's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Zosano Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Zosano Pharma has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Zosano Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Zosano Pharma's financial position?


Financial Position Analysis

Zosano Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Zosano Pharma's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Zosano Pharma's level of debt (0%) compared to net worth is satisfactory (less than 40%).

Zosano Pharma had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.


Balance Sheet

High level of physical assets or inventory.

Debt is not covered by short term assets, assets are -1.0544615577534E+16x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Zosano Pharma has less than a year of cash runway based on current free cash flow.

Zosano Pharma has less than a year of cash runway if free cash flow continues to grow at historical rates of 16.4% each year.


Next Steps

Dividend

What is Zosano Pharma's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Zosano Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Zosano Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Zosano Pharma has not reported any payouts.

Unable to verify if Zosano Pharma's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Zosano Pharma has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Zosano Pharma's salary, the management and board of directors tenure and is there insider trading?

2.2yrs

Average management tenure


CEO

John Walker (70yo)

2.3yrs

Tenure

US$5,912,946

Compensation

Mr. John P. Walker has been the Chief Executive Officer and President at Zosano Pharma Corporation since August 09, 2017 and served as its Interim Chief Executive Officer from May 9, 2017 to August 09, 201 ...


CEO Compensation Analysis

John's remuneration is higher than average for companies of similar size in United States of America.

John's compensation has increased whilst company is loss making.


Management Age and Tenure

2.2yrs

Average Tenure

56yo

Average Age

The tenure for the Zosano Pharma management team is about average.


Board Age and Tenure

3.3yrs

Average Tenure

61yo

Average Age

The tenure for the Zosano Pharma board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$350,00018 Apr 19
John Walker
EntityIndividual
Role
Chief Executive Officer
Chairman
Shares100,000
Max PriceUS$3.50

Ownership Breakdown


Management Team

  • Don Kellerman (64yo)

    Vice President of Clinical Development & Medical Affairs

    • Tenure: 4.2yrs
    • Compensation: US$794.98k
  • John Walker (70yo)

    Chairman

    • Tenure: 2.3yrs
    • Compensation: US$5.91m
  • Hayley Lewis (43yo)

    Senior Vice President of Operations

    • Tenure: 2.1yrs
    • Compensation: US$781.73k
  • Greg Kitchener (48yo)

    Chief Financial Officer

    • Tenure: 0.8yrs
  • Jeffrey Quillen

    Secretary

    • Tenure: 0.0yrs

Board Members

  • Kenneth Greathouse (66yo)

    Director

    • Tenure: 1.8yrs
    • Compensation: US$154.18k
  • Lind Grais (63yo)

    Director

    • Tenure: 0.6yrs
  • Steve Elms (56yo)

    Director

    • Tenure: 1.3yrs
    • Compensation: US$120.27k
  • Kleanthis Xanthopoulos (61yo)

    Independent Director

    • Tenure: 6.3yrs
    • Compensation: US$157.01k
  • Troy Wilson (50yo)

    Independent Director

    • Tenure: 5.2yrs
    • Compensation: US$157.01k
  • Jay Hagan (50yo)

    Director

    • Tenure: 4.3yrs
    • Compensation: US$160.01k
  • John Walker (70yo)

    Chairman

    • Tenure: 2.3yrs
    • Compensation: US$5.91m

Company Information

Zosano Pharma Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Zosano Pharma Corporation
  • Ticker: ZSAN
  • Exchange: NasdaqCM
  • Founded: 2006
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$49.093m
  • Shares outstanding: 17.72m
  • Website: https://www.zosanopharma.com

Number of Employees


Location

  • Zosano Pharma Corporation
  • 34790 Ardentech Court
  • Fremont
  • California
  • 94555
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ZSANNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJan 2015
0ZPNDB (Deutsche Boerse AG)YesCommon StockDEEURJan 2015

Biography

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its l ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/19 00:45
End of Day Share Price2019/08/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.